Patent ID: 9249468
Filing Date: 2016-02-02
CPC Classification: A61K,A61P,C12Q

Claim Text:
1. A method of diagnosing an ovarian cancer that is resistant to chemotherapeutic intervention in a subject, comprising: a) measuring, by microarray assay, miR-484, miR-642 and miR-217 expression levels in a sample of ovarian tissue from the subject, as compared to control expression levels, and b) detecting and quantifying the microarray assay of step a) to determine the levels of miR-484, miR-642 and miR-217 signature, and c) determining chemoresistant ovarian cancer in the subject if the subject has decreased miR-484, miR-642 and miR-217 expression levels compared to the control expression levels, wherein the chemoresistant ovarian cancer is resistant to therapeutic intervention from a chemotherapeutic agent selected from one or more of: a platinum-based drug, carboplatin, cisplatin, a taxane, paclitaxel, docetaxel, gemcitabine, doxorubicin, etoposide, vinorelbine, xabepilone, an epithelone drug, bevacizumab, and/or phenoxodiol, wherein step (a) comprises: 1) reverse transcribing miR-484, miR-642 and miR-217 RNA from the sample to provide a set of target oligodeoxynucleotides; 2) hybridizing the target oligodeoxynucleotides to a microarray comprising miR-484, miR-642 and miR-217 miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and 3) comparing the profile of step (2) to control.